of epinephrine and other sympathomimetic amines are well established, yet the metabolism of these compounds is poorly understood. Although several enzymes have been shown to transform these amines in vitro, the part that they play in the intact organism has been conjectural. In the past few years considerable information concerning the fate of sympathomimetic amines has become available. Many new enzymes have been found that are of importance in the transformation of these amines. This review will describe these newer developments in the metabolism and physiological disposition of catecholamine hormones and related compounds of therapeutic interest.
METABOLISM OF CATECHOLAMINES
When epinephrine or norepinephrine is administered to man (65, 66) and other species (I 31) only a small percentage of these compounds is excreted unchanged, indicating that they undergo almost complete transformation in the body. Many pathways have been proposed for the metabolism of catecholamines in vivo, but until recently, no convincing evidence has been presented showing to what extent, if any, they are involved in the transormation of exogenous or endogenous catecholamine hormones. In the past, the routes postulated for the metabolism of these amines included deamination, oxidation and conjugation. Some of these pathways will be dealt with only briefly, since they have been extensively covered in past reviews (23, 27, 30, 84).
Oxidation
In 1938, Green and Richter (79) d emonstrated that cytochrome ox&se can convert epinephrine to adrenochrome. Because of the widespread occurrence of this enzyme, it was assumed that it also metabolizes epinephrine in the body. However, Schayer has shown that the formation of adrenochrome from epinephrine in the body is unlikely (I 36). He observed that after the administration of Cr4-adrenochrome to rats, the urine contained an intensely colored yellow pigment which showed a smear of radioactivity on paper chromatograms, with no distinct peaks (I 36). After the administration of C14-epinephrine, five radioactive peaks were found (I 35). This dissimilarity in chromatographic behavior suggested that adrenochrome was not a metabolite of epinephrine. The presence of adrenochrome in the plasma of man was reported by Hoffer (86). Using a specific and sensitive method, Szara et al. failed to confirm this (I 48). In man, over go per cent of ad-
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JULIUS AXELROD Volume 39 ministered epinephrine can be accounted for by a number of metabolites, none of which have been identified as adrenochrome (I 02). The dangers of translating in vitro enzyme activity to metabolic events occurring in the intact animal might be pointed out at this time. Cytochrome oxidase metabolizes catecholamines in vitro more rapidly than any known enzyme (Axelrod, unpublished observations) but in the body it attacks catecholamines to a negligible extent. The question of how closely the results of controlled in vitro reactions parallel reactions in the body depends not only on enzyme activity, but on other competing reactions, localization and degree of binding of substrates, affinity of substrate for the enzyme, naturally occurring inhibitors, and passage of the compound across many membrane barriers to the intracellular site of metabolism.
Imaizumi and co-workers have described an enzyme, epinephrine dehydrogenase, in rabbit plasma that reversibly oxidizes epinephrine to adrenalone, diphosphopyridine nucleotide serving as the hydrogen acceptor (go, gr). These investigators have also reported that after the administration of epinephrine to guinea pigs, compounds were found in the urine that had the same R, on chromatograms as adrenalone, protocatechuic aldehyde, protocatechuic acid and norepinephrine (gg). Treatment of guinea pigs with iproniazid resulted in an increased excretion of adrenalone.
These findings indicated that the guinea pig not only oxidized epinephrine to adrenalone, but also demethylated it to norepinephrine. Weil-Malherbe and Bone did not succeed in finding the epinephrine dehydrogenase reported above (160). They have looked for this enzyme in rabbit and human plasma, and in extracts of rat liver, heart, spleen and brain. Using /3 H3-epinephrine, no evidence for the formation of adrenalone or norepinephrine has been found (13, 102).
Conjugation
Richter ingested large amounts of epinephrine, 3,4-dihydroxyephedrine, and epinine and noted that these catecholamines were excreted as sulfo-conjugates (124, 125 ).
These observations were confirmed in dogs (152) . After the oral administration of epinephrine to rabbits, it was excreted mostly as epinephrine glucosiduronic acid. On the basis of these results, it was concluded that conjugation constituted an important pathway for the metabolism of catecholamines. According to more recent studies, the intravenous administration of :hysiological doses of catecholamines led to the excretion of only small amounts of conjugated catecholamines (65, 66, I 3 I). It is now generally believed that conjugation plays a minor role in the inactivation of physiological amounts of catecholamines. In the earlier experiments, the massive amounts of the catecholamines given may have overwhelmed the normal enzymatic mechanisms. Furthermore, after oral ingestion, the intestinal flora may have conjugated these amines before they were absorbed.
Deamination by Monoamine Oxidase
A number of investigators (3 I a, I I 6, I 22) have demonstrated that epinephrine serves as a substrate for monoamine oxidase. Since this observation was made, monoamine oxidase has been considered by many to be the enzyme chiefly concerned with the metabolism of epinephrine and other catecholamines in the intact organism (see refs. 30 and 53 for reviews on this subject). Burn (41) postulated that monoamine oxidase acts at the sympathetic nerve endings in the same manner as acetylcholine esterases in the parasympathetic system. This assumption rested mainly on the fact that monoamine oxidase is present in the autonomic nervous system and that after denervation of the nictitating membrane, iris and blood vessels in cats, a decrease in the enzyme was found in these tissues (43). A correlation between the fall in enzyme activity and increased sensitivity to norepinephrine was also observed. Armin et al. (3), however, showed that after sectioning of the sympathetic nerves amine oxidase persisted undiminished, while acetylcholine esterase activity was markedly reduced. They attributed the hypersensitivity to epinephrine after denervation to a reduction of acetylcholine esterase rather than amine oxidase. When the urine of rats that received p Cr4-epinephrine was subjected to paper chromatography, five radioactive metabolites retaining the @ carbon were found (130). Except for epinephrine, none of these compounds was identified. Paper chromatograms of urine of rats to which N-methyl C14-epinephriLe was given showed only three radioactive metabolites, one of which was epinephrine (135) .
From these experiments it appeared that epinephrine formed two major metabolites that retained the methyl amino group and two in which this group was removed. found that metanephrine (3-0-methylepinephrine) and normetanephrine (3-0-methylnorepinephrine), in free and conjugated form, occur normally in rat urine, and that the excretion of these compounds was markedly elevated when epinephrine and norepinephrine were given to rats. These results demonstrated that the catecholamines undergo 0-methylation before deamination. The extent to which 0-methylation of epinephrine occurs was examined after intraperitoneal injection of physiological amounts of /3 H3-epinephrine to rats (13, 16) . After collecting the urine for 24 hours, the 0-methylated metabolites were extracted into organic solvents (I 8). About 87 per cent of the administered radioactivity appeared in the urine, 55 per cent of which was identified as free metanephrine and metanephrine glucosiduronic acid. Twelve per cent of the radioactivity was present as 3-methoxy-4-hydroxymandelic acid and only traces as 3,4 dihydroxymandelic acid. After the administration of 1argP amounts of epinephrine or metanephrine to rats, smaller percentages of metanephrine (free and conjugated) appeared in the urine (16). To study the sequential steps in the biotransformation of epinephrine, metanephrine was given to rats and its metabolic fate examined (13, 16). About the same amounts of metanephrine (free and conjugated) and 3-methoxy-4-hydroxymandelic acid were excreted after metanephrine as were found after epinephrine, indicating that 3-methoxy-4-hydroxymandelic acid is derived from metanephrine rather than 3,4-dihydroxymandelic acid. When rats were pretreated with iproniazid, virtually all the administered epinephrine or metanephrine was excreted as free and conjugated metanephrine.
METABOLISM
The metanephrine excretion increased at the expense of 3-methoxy-4-hydroxymandelic acid. A major metabolic product found after the administration of norepinephrine to rats was normetanephrine (16). Pretreatment with iproniazid resulted in a twofold increase in the excretion of normetanephrine.
These observations provided strong evidence that, in rodents, 0-methylation is the first step in the metabolism of catecholamines in vivo, and that monoamine oxidase is concerned in the deamination of the O-methyl amines. Normetanephrine and metanephrine were found to occur normally in adrenal gland, spleen (I 8), pheochromocytoma tumors (I 42) and urine (I 8, I 03). Normal occurrence of 0-methylated amines in tissues rich in epinephrine and norepinephrine as well as in urine would indicate that the endogenous catecholamines are also 0-methylated. However, the extent to which endogenous catecholamines are 0-methylated remains to be established. The presence of large amounts of 3-methoxy-4-hydroxymandelic acid (4) and normetanephrine (103) in the urine of human subjects with pheochromocytomas suggests that 0-methylation is an important route of metabolism of catecholamines in man. After the intravenous infusion of physiological doses of /3 H3-epinephrine, about go per cent of the radioactivity appeared in the urine. Fifty-five per cent of the radioactivity was free and conjugated metanephrine and 30 per cent was 3-methoxy-4-hydroxymandelic acid (102). Kirshner et al. found essentially similar results in man (98). In rats, metanephrine is conjugated with glucuronic acid, while in man it is conjugated presumably with sulfuric acid. An additional metabolite, present in small quantities, was tentatively identified as 3,4-dihydroxymandelic acid (98, 121). When metanephrine was administered to man, the same fraction was excreted as metanephrine and 3-methoxy-4-hydroxymandelic acid as was observed after epinephrine (102), indicating that the acid arises mainly from the deamination of metanephrine.
In iproniazid-treated subjects the excretion of metanephrine is increased, while that of 3-methoxy-4-hydroxymandelic acid is decreased (I 30).
Normetanephrine and metanephrine possess relatively weak physiological and psychological activity (68, 102) suggesting that 0-methylation of catecholamines is an inactivation process. In the light of these findings, it can be concluded that the principal pathway for the metabolism of epinephrine and norepinephrine in man and rodents is. 0-methylation to metanephrine or normetanephrine, the latter amines being in turn either deaminated by monoamine oxidase or conjugated. Direct deamination of these catecholamines appears to be a minor route of transformation. The pathways for the metabolism of epinephrine and norepinephrine are shown in figure 2. A new metabolic product of epinephrine and norepinephrine, 3-methyoxy-4-hydroxyphenylglycol, has been identified in this laboratory (Axelrod, Kopin and Mann, unpublished observations). The metabolite arises from the deamination of metanephrine or normetanephrine followed by reduction of the resulting 3-methoxy-4-hydroxyphenylglycol aldehyde. this enzyme has been confirmed by other investigators (75, 105, I 15). Incubating the soluble supernatant fraction of rat liver with epinephrine, S-adenosylmethionine and Mg++ resulted in the disappearance of one mole of the catecholamine and the appearance of one mole of metanephrine.
In the absence of S-adenoslymethionine or Mg++ negligible metabolism occurred (I I, 20). These observations demonstrated that the enzyme transfers the methyl group of S-adenosylmethionine to the 3-hydroxy group of epinephrine.
Catechol-O-methyl transferase is widely distributed among b variety of species and tissues (table I) and is localized in the soluble fraction of the cell (14, 20) . Of all the tissues examined, enzyme activity is found to be consistently highest in the liver, while the activity in monkey liver is greater than in any other mammalian species examined.
Particularly noteworthy is the high catechol-O-methyl transferase in such glandular tissues as salivary gland, pancreas and adenohypophysis (14) . The magnitude of enzyme activity is the same in thyroid gland, spleen, blood vessels and brain in the monkey. Catechol-O-methyl transferase activity is also found in all peripheral nerves (I 4). The presence of this enzyme in those organs upon which norepinephrine and epinephrine exert their effects suggests that it might act locally in the transformation of these hormones. The enzyme requires reduced triphosphopyridine nucleotide and appears to be similar to other 0-demethylating enzymes (I 0).
A major route of metabolism of 0-methylated amines in some animal species involves conjugation with glucuronic acid on the hydroxy group. The synthesis of glucuronides has been shown to be catalyzed by an enzyme system in the microsomes of liver, and requires uridine diphosphate glucuronic acid as the glucuronide donor (55, 92). Incubation of metanephrine or normetanephrine with microsomes of rat liver and uridine diphosphate glucuronic acid resulted in the formation of the corresponding glucosiduronic acid of these amines (unpublished).
FORMATION AND METABOLISM OF CATECHOLAMINES IN NERVOUS

SYSTEM
The presence and role of norepinephrine in the autonomic nervous system has been well established (61 were found (I 59). It was concluded from these experiments that epinephrine is unable to cross the blood-brain barrier, except to a small extent in the hypothalamus (I 59). Since epinephrine is present in the brain (I 55), it must be formed from precursors which are able to cross the bloodbrain barrier. It is probable that norepinephrine in the brain is formed from dopa, a compound that can cross the blood-brain barrier (46). Both dopa (I IO) and dopamine (46, I IO) were found to occur normally in the brain of a number of mammalian species. Moreover, the intravenous injection of dopa to rabbits caused a considerable rise in the dopamine content of the brain (46). Pretreatment with iproniazid markedly enhanced the dopamine levels, but had little or no effect on norepinephrine levels in the brain (47). The presence of the deaminated product of dopamine, dihydroxyphenylacetic acid, in the splenic nerve (62) and brain (I I o) has also been reported.
These observations would suggest that in the nervous system dopamine is readily attacked by monoamine oxidase.
The manner in which the actions of the catecholamines in the nervous system are terminated is poorly understood. For many years, monoamine oxidase has been considered to be the principal enzyme involved in the inactivation of norepinephrine and epinephrine.
However, since the introduction of monoamine oxidase inhibitors, considerable doubt has been cast upon the role of this enzyme in the metabolism of epinephrine and norepinephrine.
(See above for a review of this subject.)
Recently, 0-methylation has been shown to be the principal pathway for the metabolism of administered epinephrine and norepinephrine (16, 102) .
Normetanephrine has been found to be present in organs rich in sympathetic fibers (18) and in the brain extract of rats treated with iproniazid (I 2). When Xormetanephrine was incubated with brain mitochondria and aldehyde dehydrogenase, it was oxidatively deaminated to 3-methoxy-4-hydroxymandelic acid (I 2). This indicates that the endogenous norepinephrine could be 0-methylated in the nervous system and then further metabolized.
The enzyme, catechol-O-methyl transferase, which catalyzes the first reaction, has been found to be present throughout the nervous system, including the brain, sympathetic ganglia and postganglionic sympathetic fibers, as well as parasympathetic, motor and sensory nerves (table I and ref. 14). Within the central nervous system differences of enzyme activity ranging up to fourfold were found (I 4). The lowest values occurred in the cerebral cortex and amygdala, and the highest in the neurohypophysis.
There was no direct relationship between catechol-O-methyl transferase activity found in various regions of the monkey brain and norepinephrine levels reported in different areas in the dog brain. The Michaelis constant (Km) of catechol-0-methyrl transferase with respect to brain epinephrine is less than IO-~ M, which places it in the physiological range of tissue catecholamine concentrations (I 4). Although direct evidence of the main pathway of metabolism of the catecholamines in the nervous system is lacking, it appears likely that catechol-O-methyl transferase is an important enzyme.
S-adenosylmethionine, the donor of active methyl groups (45), is assuming considerable importance in the metabolism of biologically active amines. The cofactor is involved in the 0-methylation of catecholamines (I I), the N-methylation of norepinephrine to epinephrine (g7), and more recently it has been shown to be required for the conversion of histamine to methyl histamine (38). The latter reaction is of paramount importance in the inactivation of histamine (133). The ability of the nervous system to synthesize S-adenosylmethionine from adenosine triphosphate and methionine has been established (I 4).
PHYSIOLOGICAL DISPOSITION OF EPINEPHRINE
There is considerable information available concerning the localization of endogenous catecholamines (61). However, relatively little is known about the disposition of these hormones when they are released from the adrenal medulla and sympathetic nerve endings, or when administered intravenously. Raab and Gigee (I I 7, I I 8) reported that epinephrine and norepinephrine were selectively taken up by heart muscle and other vascular tissues when massive doses of these compounds were administered to cats or dogs, but there was no demonstrable increase in the catecholamine content with doses below 2 milligrams per kilogram. Von Euler (60), on the other hand, did not find any significant changes in the catecholamine content of heart, spleen, liver, kidney or skeletal muscle of the cat when large or small amounts of catecholamines were given. These contradictory results might be due to the lack of precision and specificity of the methods employed. More recently, the physiological disposition of epinephrine and its melabolite, metanephrine, was examined in cats and mice after an intravenous infusion of physiological amounts of tritium-labeled /3 DL H3-epinephrine of high specific activity (22) . The amines were separately determined by specific procedures involving column chromatography and extraction in organic solvents. Immediately after the end of a go-minute infusion (3 pg/min/kg) the concentration of H3-epinephrine in heart, spleen, adrenal and pituitary gland exceeded that of the plasma several-fold.
In kidney, liver, lung and intestines, its concentration was of the same magnitude as that of the plasma, while it was lower in skeletal muscle. After an intravenous infusion of radioactive epinephrine, Weil-Malherbe et al.
found negligible amounts of radioactive epinephrine in the brain of the cat, while Schaepdryver (129) reported significant amounts of the radioactive catecholamine in the brain of the dog. Two hours after the administration of H3-epinephrine, large quantities were found in heart and spleen, indicating that these tissues not only accumulate the hormone, but also retain it for long periods of time. Immediately after H3-epinephrine infusion, the concentration of metanephrine in plasma was about the same as that of epinephrine (22) .
The O-methylated metabolite accumulated in heart, spleen, adrenal gland and liver, but insignificant amounts were found in the brain, indicating that metanephrine crosses the blood-brain barrier with difficulty. After the intravenous injection of epinephrine in rabbits and dogs, Pekkarinen (I 13) and Lund (106) reported that the amine was completely eliminated from the blood within IO minutes. Norepinephrine disappeared from the plasma even more rapidly than epinephrine (106).
An intravenous injection of H3-epinephrine was followed by a precipitous fall in the plasma levels of the amine within 5 minutes (228). In contrast to the earlier findings, however, small but significant amounts of epinephrine were present in the plasma for more than 2 hours (22a, 129). Within 2 minutes after the intravenous injection of H3-epinephrine, its metabolite, metanephrine, reached a peak level in the plasma, with approximately the same or higher concentrations as that of epinephrine (25). Only small amounts of 3-methoxy-4-hydroxymandelic acid and 3,4dihydroxymandelic acid (less than one-tenth that of metanephrine)
were present in the plasma at that time (22a). These observations indicate that during the period of physiological inactivation of epinephrine, catechol-O-methyl transferase is the predominating enzyme. The disappearance of the metanephrine from the plasma then closely paralleled that of epinephrine ( fig. 3) . The initial drop in the plasma level was presumably due to passage into the tissues, as well as metabolic transformation.
The dynamic factors involved in the elimination of epinephrine in the intact organism were examined in the mouse (22a).
After the intravenous injection of 3 micrograms of H3-epinephrine to mice, the catecholamine and its metabolite were determined in the whole animal at various time intervals. Within IO minutes, more than half of the epinephrine disappeared. After I o minutes, the amine disappeared much more slowly; more than IO per cent of the administered epinephrine was still found in the mouse after 3 hours. The rate of elimination of epinephrine in the whole mouse was independent of the amount of epinephrine administered over a range of I-IO micrograms of injected epinephrine per mouse. In the initial phase, I mole of metanephrine appeared in the whole mouse for every mole of epinephrine eliminated.
These observations, together with those described above, suggest the following sequence of events in the elimination of circulating epinephrine: first phase (o-5 minutes), rapid dilution by redistribution into tissues, 0-methylation by catechol-O-methyl transferase and binding onto certain tissues; second phase (5-180 minutes or longer), slow release of epinephrine from binding sites, followed by attack by catechol-O-methyl transferase.
METABOLISM OF PHENYLETHYLAMINES
Studies on the metabolism of amines with a phenylethylamine nucleus were initiated in I 910 by Ewins and Laidlow (69) who found that the administration of phenylethylamine and tyramine to dogs, cats and rabbits resulted in the excretion of large amounts of phenylacetic acid and p-hydroxyphenylacetic acid, respectively.
Guggenheim and Liiffler confirmed these findings in rats and mice (81). More recently, Schayer reported that about go per cent of C?* tyramine was excreted as free and conjugated p-hydroxyphenylacetic acid and IO per cent as free and conjugated tyramine (I 32). These observations suggested the presence of an enzyme that could deaminate these amines in vivo.
In Alles and Heegard (I) have determined the relative rates of deamination of a number of phenylamines.
From the data obtained in these studies, it was suggested that more than one enzyme may be involved in the deamination of monoamines.
This is also the view of Werle and Roewer (163), who believe that in ox liver, tyramine and n-butylamine are oxidized by two enzyme systems. Recently other amine oxidases have been identified, one isolated from ox plasma which shows marked activity towards spermine and spermidine (I 4g), and another enzyme localized in liver microsomes which deaminates phenylisopropylamines (9). The further purification of monoamine oxidase (161) may make it possible to uncover other closely related amine oxidases.
The evaluation of monoamine oxidase in the metabolism of phenylethylamine derivatives in vivo was made possible by the introduction of potent monoamine oxidase inhibitors such as iproniazid (165) and choline-p-tolyether bromide (40). Pretreatment with iproniazid markedly prolonged the contraction of the nictitating membrane of the cat when phenylethylamine or tyramine was administered (80). The toxic action of phenylethylamine and tyramine, but not of ephedrine, was increased by pretreating guinea pigs with iproniazid (I 20). In mice, iproniazid or choline-p-tolylether bromide caused a pronounced increase in the excretion of Cl* tyramine after the administration of the latter substance (I 32). Several compounds, such as ephedrine, amphetamine and cocaine, which inhibit monaomine oxidase in vitro, were found to have no effect in vivo (I 32).
The metabolism of mescaline (3,4,5-trimethoxy phenylethylamine), the active psychotomimetic principle of 'mescal buttons,' has been the subject of many studies. After its administration to dogs and rabbits, Slotta and Muller (I 43) recovered large amounts of 3 ,4,5-trimethoxy phenylacetic acid in the urine. These results could not be confirmed by Cochin et al. (49). In man and dog, a major fraction of mescaline is excreted unchanged (49, 123, 127 ). An interesting minor metabolite found in the urine of man after the ingestion of mescaline was identified as a conjugate of 3 ,qdihydroxy-5-methoxyphenylacetic acid, indicating that this molecule can undergo 0-demethylation.
Despite the fact that mescaline contains a phenylethylamine nucleus, it is metabolized by diamine oxidase, rather than monoamine oxidase (166). Mescaline is also 0-demethylated by an enzyme localized in the microsomes of the liver (IO). After the administration of mescaline to the dog, the amine is widely distributed in all organ tissues, including the brain Phenylisopropylamines constitute an important segment of the sympathomimetic amines, yet until recently little was known about the disposition and metabolism of these compounds.
Richter (123) reported that when the phenylisopropylamines ephedrine and amphetamine were administered to man, they were excreted in the urine almost entirely unchanged. He ascribed the stability of the drugs in vivo to the failure of monoamine oxidase to attack these compounds. Other investigators (6, 7, 29, 93, 96) d d i not corroborate these findings. They found that considerable amounts of administered phenylisopropylamines were metabolized in man, dog and rabbit. Moreover, when the liver function of dogs was impaired by the administration of carbon tetrachloride, the urinary excretion of amphetamine was increased (29).
In the past, studies on the fate of phenylisopropylamines have been hampered by the lack of sensitive and specific methods for the estimation of these compounds in biological materials. The development of methods for the estimation of amphetamine, p-hydroxyamphetamine (Paradrin), methamphetamine, ephedrine, norephedrine (Propadrine), p-hydroxyephedrine (Suprifen) and p-hydroxynorephedrine has made possible a study of the metabolism of these compounds in vivo and in vitro (6, 7).
The accompanying scheme ( fig. 4) describes the metabolic transformation of amphetamine in vivo (7). The main route of metabolism of n-amphetamine in the dog involves hydroxylation to p-hydroxyamphetamine, a potent pressor agent. After the administration of L-amphetamine, however, only small amounts of@-hydroxyamphetamine are excreted. The differences in the metabolism of the optical isomers of amphetamine are presumably due to a stereospecific enzyme (9) which can deaminate the levo isomer of amphetamine more readily than the dextro isomer. In the dog
n-amphetamine disappears more slowly than its hydroxylated metabolite, suggesting that in this species at least, the major pressor effect is mediated by the parent compound. When hydroxyamphetamine is administered, it appears in the urine partly free and partly conjugated. After the administration of methamphetamine to a dog, about half the compound is demethylated to amphetamine, part of which is hydroxylated to p-hydroxyamphetamine. From these observations, it appears that the pharmacological action of methamphetamine is mediated through its metabolic product, amphetamine.
There are marked differences in the metabolism of n-amphetamine in various species. Dogs The enzyme which deaminates amphetamine differs from other deaminating enzymes such as amine oxidase, n-amino acid oxidase, L-amino acid oxidase and glutamic acid dehydrogenase with respect to its substrate specificity, intracellular localization and cofactor requirements (9). The role of TPNH in an enzyme system catalyzing the oxidative deamination of an amine is not understood. TPNH could conceivably act by the generation of hydrogen peroxide through the transfer of hydrogen by an intermediate electron transport system to molecular oxygen. However, hydrogen peroxide generated from n-amino acid oxidase was unable to replace TPNH in the deamination of amphetamine.
Gillette et al. (76) have found that TPNH is oxidized by an enzyme in liver microsomes in the absence of amine substrate to form a 'peroxide.' These investigators believe that the oxidation of TPNH is necessary to carry out other metabolic reactions in the microsomes.
In addition to amphetamine, a number of other amines are deaminated by the TPNH-dependent enzymes in the microsomes (9). Amines having a phenylisopropylamine or phenylbutylamine structure are extensively transformed by the enzyme, while phenolic-substituted amines, phenylethylamines and aliphatic amines are metabolized slightly or not at all. The enzyme also has some degree of stereospecificity, since the L-isomers of amphetamine are transformed more rapidly than the n-isomers. The deaminating activity of rabbit liver microsomes is considerably depressed when rat microsomes are added. Heating of the rat liver microsomes unmasks the presence of a heat-stable activator for this reaction. The nature of this activating factor is unknown.
Species differences in the metabolism of amphetamine may in part be explained by the presence of inhibitory and activating factors in liver microsomes (9).
Following the observation that an enzyme in the microsomes of liver requiring TPNH and oxygen can deaminate amphetamine, many TPNH-dependent enzyme systems have been found that carry out a wide variety of reactions. Metabolic transformations catalyzed by these enzyme systems include N-demethylation (8, 104), hydroxylation of aromatic compounds (rag), side chain oxidation (51) and cleavage of ethers (IO) . A review of this subject has been published (37). The relative nonspecificity of the substrates atacked by the microsomal enzymes would suggest that they act as 'scavenger' enzymes and perform normal roles as well. Another property common to microsomal enzyme systems is their inhibition by /3-diethylaminoethyl diphenylpropylacetate (SKF 525A, refs. I 7, 50). This compound has little pharmacological activity of its own, but prolongs the action of sympathomimetic amines as well as other pharmacological agents by inhibiting microsomal enzyme systems which are concerned with the inactivation of these compounds.
Beyer (25) has observed that ascorbic acid can deaminate a number of phenylethylamines and phenylisopropylamine derivatives nonenzymatically. This was substantiated in z&o for amphetamine when it was reported that the excretion of the amine in dogs could be markedly diminished by the subcutaneous injections of large amounts of ascorbic acid (26). When the injections were discontinued, the excretion of amphetamine increased again. It has been reported that ascorbic acid in the presence of Fe++, versene and oxygen hydroxylates aromatic compounds in the test tube (36, I 51). Thus, in the model chemical system, tyramine is oxidized to dopamine (36) and amphetamine and ephedrine are hydroxylated to their corresponding para derivatives (36). I n ascorbic acid-deficient guinea pigs the rate of the hydroxylation of aromatic compounds was reduced (21). The precise role that ascorbic acid plays in the metabolism of amines in the organism is not known. Figure 5 shows the route of metabolism of ephedrine (6). The principal pathway of biotransformation of ephedrine in Ihe dog involves eph~~. 5. Metabolism of rapid N-demethylation to norephedrine, a relatively stable and potent pressor agent. It is probable that the activity of ephedrine is mediated to a considerable extent through its metabolite, norephedrine.
Other minor routes of metabolism involve hydroxylation of both ephedrine and norephedrine to yield the corresponding P-hydroxy derivatives, both of which are potent pressor agents. No evidence has been found for the excretion of 3,4dihydroxyephedrine. However, these catecholamines are readily 0-methylated by catechol-0-methyltransferase, and if formed, they might be further metabolized to their corresponding O-methyl derivatives. Norephedrine is relatively stable, and is excreted in the urine mainly unchanged. Calculations of the renal excretion of norephedrine from plasma levels and urinary excretion yielded values which were considerably higher than the glomerular filtration rate, suggesting that a secretory transport mechanism is involved in its excretion (6).
There are differences in the metabolism of ephedrine in mammalian species. In the dog and guinea pig, demethylation proceeds rapidly, constituting a major route of biotransformation.
The rat, on the other hand, demethylates ephedrine slowly and considerable amounts of the drug are excreted both unchanged and as hydroxylated derivatives.
Only very small quantities of norephedrine and ephedrine are eliminated by the rabbit, indicating that in this species ephedrine is demethylated to norephedrine, which in turn is extensively metabolized by pathways other than hydroxylation.
After the subcutaneous administration of 3,4dihydroxynorephedrine to man, only small amounts of the compound are excreted unchanged (67), indicating almost complete metabolic alteration of the molecule. Although the metabolic products of this catechol have not been identified, it is probable that it is O-methylated and excreted as free or conjugated 3-methoxy-a-hydroxynorephedrine.
Ephedrine is Ndemethylated to norephedrine and formaldehyde by a TPNH-dependent enzyme system in the microsomes of the liver (8). The over-all reaction can be represented by the following equation:
The microsomal preparation also metabolizes ephedrine by pathways other than demethylation (8). The ability of the microsomal enzyme system to demethylate other sympathomimetic amines is dependent on the structure of the amine: Substrates possessing a phenylisopropylamine nucleus are extensively demethylated, while those with a phenylethylamine nucleus are not. Amines with hydroxy groups on the aromatic nucleus are demethylated slightly or not at all. Species differences in the metabolism of ephedrine can be explained in part by the activity of the TPNH-dependent microsomal demethylating enzyme as compared to the deaminating enzyme. When ephedrine or norephedrine are administered to the rabbit, both compounds are extensively metabolized.
The transformation of these amines is catalyzed by enzymes which demethylate ephedrine and deaminate norephedrine.
In the dog the activity of the norephedrinedeaminating enzyme is low, so that the demethylated ephedrine, once formed, is excreted unchanged. The activity of the enzymes which demethylate ephedrine and deaminate norephedrine in the rat is negligible, so that administered ephedrine in this species is excreted unchanged or as p-hydroxyephedrine.
The tissue concentration of the phenylisopropylamines amphetamine, ephedrine and norephedrine, shows a similar pattern of distribution (6, 7). After their administration, these compounds are localized in organ tissues to a considerable extent, with small amounts in the bile and fat. The high concentration of the amines found in the brain and cerebrospinal fluid suggests that there is little hindrance to their passage across the blood-brain barrier. Catecholamines, on the other hand, cross the blood-brain barrier with difficulty or not at all (I 59).
METABOLISM 0F IND~LAMINE~
The metabolism of the indolamine, tryptamine, has been elucidated by Ewins and Laidlow many years ago (70) . After its administration, it is deaminated to g-indolacetic acid, which is then excreted as a glycine conjugate. Since tryptamine is a substrate for monoamine oxidase (7, 31, 31 a) it has been assumed that this enzyme deaminates the amine in the intact organism. More recently, Schayer et al. (I 37) have shown that the inhibition of monoamine oxidase in viuo increases the excretion of administered
tryptamine. An indole base with an R, value corresponding to that of tryptamine has been found in normal urine (I 26). Tryptamine has also been found in tissues, including brain and liver, following the administration of a monoamine oxidase inhibitor and tryptophan (85). Although the decarboxylation of tryptophan has been demonstrated in ho (I 58, I 62) the origin and physiological significance of tryptamine in the body have yet to be established.
In the past IO years, tryptamine derivatives have acquired a new significance when serotonin (5-hydroxytryptamine) was found to be a normal constituent in the body (I I 9). The presence of serotonin in the brain (2, 150) and the provocative proposal of Wooley (164) and Gaddum (73) that this amine may be involved in the maintenance of mental health, stimulated great activity in this area of research. An exhaustive review of this subject has been published recently by Page (I 12) , and the metabolism of serotonin will be covered only briefly here. Serotonin has been shown to arise from tryptophan in the body (I 54). Although tryptophan and 5-hydroxytryptophan form serotonin in man, tryptamine does not (152), indicating that hydroxylation of the indole nucleus precedes decarboxylation. A major pathway for the metabolism of serotonin is deamination by monoamine oxidase and aldehyde dehydrogenase to 5-hydroxyindolacetic acid (I 53) which is then conjugated with glycine and excreted in the urine. Other, though minor, routes for the metabolism of serotonin involve N-acetylation and conjugation with glucuronic acid (I 08).
Szara has described the psychotomimetic actions of dimethyltryptamine (I 46). After its administration, this compound is excreted in the urine as g-indolacetic acid in the rat (57) and man (146). Recently, new pathways for the metabolism of In vitro studies have shown that N-demethylation (147) and 6-hydroxylation (94, I 47) of the indolamine is catalyzed by TPNH-dependent enzymes in the liver microsomes.
Although the indole-containing ergot alkaloids are widely used as pharmacologic agents, little is known about their biologic fate. One of these compounds, lysergic acid diethylamide (LSD), a potent hallucinogenic compound, is readily hydroxylated to 2-oxy-LSD by a microsomal enzyme in the liver of a number of mammalian species (I 5). Other ergot alkaloids may be hydroxylated in the same manner. When administered, LSD is almost completely altered in the body, and there are species differences in the rate of biotransformation of the compound (I 5). From the amount of LSD found in the brain of cats, it was calculated that the drug exerts its psychological effect at an exceedingly minute concentration.
SUMMARY
Routes for the metabolism of catecholamines in vivo have been estab'lished the past few years. The major pathway for the metabolism of epinephrine and norepinephrine involves 0-methylation to yield metanephrine and normetanephrine. These physiologically inactive metabolites are then conjugated or deaminated to 3-methoxy-4-hydroxymandelic acid. A considerable body of evidence has accumulated indicating that monoamine oxidase is mainly concerned with the deamination of the 0-methylated metabolites, rather than the catecholamines themselves.
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